期刊文献+
共找到10篇文章
< 1 >
每页显示 20 50 100
聚乙二醇化重组抗血友病因子治疗A型血友病研究进展 被引量:1
1
作者 高雯(综述) 陈姝(审校) 《现代医药卫生》 2020年第11期1674-1677,共4页
随着多种重组凝血因子Ⅷ产品的出现,延长重组凝血因子Ⅷ的疗效成了研究热点。聚乙二醇(PEG)化重组抗血友病因子[pegylated antihemophilic factor recombinant,商品名:Adynovate(BAX 855)]是重组抗血友病因子(recombinant,商品名:Advate... 随着多种重组凝血因子Ⅷ产品的出现,延长重组凝血因子Ⅷ的疗效成了研究热点。聚乙二醇(PEG)化重组抗血友病因子[pegylated antihemophilic factor recombinant,商品名:Adynovate(BAX 855)]是重组抗血友病因子(recombinant,商品名:Advate)的长效版,采用了PEG化技术延长药物在体内的半衰期(T 1/2)[1],与未经修饰的抗血友病因子相比,PEG化重组抗血友病因子将为治疗A型血友病及降低出血风险提供更可靠的治疗选择[2]。 展开更多
关键词 血友病A型 长效凝血因子Ⅷ 乙二醇化重组血友病因子 替代治疗
下载PDF
用折光率计算水-乙二醇抗燃液压液中的水含量
2
作者 于丽杰 《合成润滑材料》 CAS 2018年第1期15-16,共2页
水-乙二醇型抗燃液压液的折光率会随水分而发生变化,建立折光率与水分的关系式,可以利用折光率来计算水-乙二醇型抗燃液压液中的水分。采用绘制水-乙二醇型抗燃液压液折光率与水分标准曲线的方法,建立了折光率与水分的回归方程。水-乙... 水-乙二醇型抗燃液压液的折光率会随水分而发生变化,建立折光率与水分的关系式,可以利用折光率来计算水-乙二醇型抗燃液压液中的水分。采用绘制水-乙二醇型抗燃液压液折光率与水分标准曲线的方法,建立了折光率与水分的回归方程。水-乙二醇型抗燃液压液中的水分质量分数在38.0%~43.0%的范围内,该回归方程计算出的水分与实测水分基本一致,相对误差在±4.0%以内。 展开更多
关键词 水-乙二醇燃液压液 折光率 水分 回归方程
下载PDF
气井泡排剂SCF-1的室内研究 被引量:5
3
作者 李进 徐杰 +2 位作者 王明凤 石亚琛 雷佳霖 《当代化工》 CAS 2016年第10期2292-2295,共4页
以十二烷基硫酸钠(SDS)、椰油酰胺丙基甜菜碱(CKD)为主剂,氟碳型特种表面活性剂FC-03为稳定剂,确定SDS、CKD、FC-03最佳配比为3:1:0.24,研制出一种独特的抗油、抗盐、抗乙二醇复配泡排剂SCF-1,与现场常用泡排剂UT-11C、UT-10B进行对比... 以十二烷基硫酸钠(SDS)、椰油酰胺丙基甜菜碱(CKD)为主剂,氟碳型特种表面活性剂FC-03为稳定剂,确定SDS、CKD、FC-03最佳配比为3:1:0.24,研制出一种独特的抗油、抗盐、抗乙二醇复配泡排剂SCF-1,与现场常用泡排剂UT-11C、UT-10B进行对比。实验表明:复配泡排剂SCF-1不仅具有优异的抗凝析油能力,在高矿化度、高乙二醇的情况下仍能保持高效。 展开更多
关键词 抗乙二醇 泡沫高度 携液量
下载PDF
“加速血流清除”现象中的免疫机制分析 被引量:5
4
作者 佘振南 翟文俊 邓意辉 《沈阳药科大学学报》 CAS CSCD 北大核心 2011年第9期760-768,共9页
目的对"加速血流清除"(accelerated blood clearance,ABC)现象的产生机制和影响因素进行综述,并探讨可能的解决途径。方法参阅近年来国内外文献共42篇,从免疫学角度对聚乙二醇(polyethyleneglycol,PEG)化脂质体ABC现象的产生... 目的对"加速血流清除"(accelerated blood clearance,ABC)现象的产生机制和影响因素进行综述,并探讨可能的解决途径。方法参阅近年来国内外文献共42篇,从免疫学角度对聚乙二醇(polyethyleneglycol,PEG)化脂质体ABC现象的产生机制与影响因素进行归纳、总结和分析。结果首次注射的PEG化脂质体作为抗原诱发机体分泌特异性抗体,此抗体与二次注射的PEG化脂质体相结合并介导其从血液中加速清除。PEG包衣、PEG植入密度、载体粒径/大小、载体电荷、磷脂剂量、给药间隔及包封药物等因素均对脂质体的ABC现象产生影响。结论为解决PEG化脂质体ABC现象及PEG化制剂的开发提供了参考。 展开更多
关键词 加速血液清除 乙二醇 脂质体 免疫 胸腺非依赖原2型 -聚乙二醇免疫球蛋 白M
下载PDF
New therapeutic vaccination strategies for the treatment of chronic hepatitis B 被引量:9
5
作者 Jia Liu Anna Kosinska +1 位作者 Mengji Lu Michael Roggendorf 《Virologica Sinica》 SCIE CAS CSCD 2014年第1期10-16,共7页
Chronic hepatitis B virus(CHB) is currently treated with either interferon-based or nucleot(s)idebased antiviral therapies.However,treatment with pegylated interferon alpha results in a durable antiviral response in o... Chronic hepatitis B virus(CHB) is currently treated with either interferon-based or nucleot(s)idebased antiviral therapies.However,treatment with pegylated interferon alpha results in a durable antiviral response in only about 30%patients and is associated with side effects.Most patients receiving nucleot(s)ide analogue treatment do not establish long-term,durable control of Infection and have rebounding viremia after cessation of therapy.Thus,novel therapy strategies are necessary to achieve the induction of potent and durable antiviral immune responses of the patients which can maintain long-term control of viral replication.Therapeutic vaccination of HBV carriers is a promising strategy for the control of hepatitis B.Here the authors review new therapeutic vaccination strategies to treat chronic hepatitis B which may be introduced for patient treatment in the future. 展开更多
关键词 hepatitis B virus woodchuck hepatitis virus therapeutic vaccination IMMUNOMODULATION programmed death-1
下载PDF
治疗血友病A新药:聚乙二醇重组抗血友病因子 被引量:1
6
作者 陶妙婴 《中国新药与临床杂志》 CAS CSCD 北大核心 2018年第3期139-142,共4页
聚乙二醇重组抗血友病因子(Adynovate)建立在重组抗血友病因子(Advate)基础上,是聚乙二醇化的重组凝血因子Ⅷ,用于成人和青少年血友病A患者出血发作的按需治疗与控制以及常规预防治疗以减少出血发作的频次。2015年11月13日,美国FDA批准A... 聚乙二醇重组抗血友病因子(Adynovate)建立在重组抗血友病因子(Advate)基础上,是聚乙二醇化的重组凝血因子Ⅷ,用于成人和青少年血友病A患者出血发作的按需治疗与控制以及常规预防治疗以减少出血发作的频次。2015年11月13日,美国FDA批准Adynovate上市。Adynovate的临床疗效和安全性与Advate相似,但Adynovate在生物体内具有更长的半衰期,作用时间更长,可以减少给药频次。 展开更多
关键词 血友病A 因子Ⅷ 药动学 乙二醇重组血友病因子 治疗结果
原文传递
Preventive and therapeutic effects of Aerva lanata(L.) extract on ethylene glycol-induced nephrolithiasis in male Wistar albino rats
7
作者 Ankul Singh S Chitra Vellapandian Gowri Krishna 《Digital Chinese Medicine》 2022年第2期199-209,共11页
Objective Nephrolithiasis is a common urological disease. This study aims to evaluate the preventive and therapeutic effects of hydro-alcoholic extract of Aerva lanata(L.) roots(HAEAL) on ethylene glycol-induced nephr... Objective Nephrolithiasis is a common urological disease. This study aims to evaluate the preventive and therapeutic effects of hydro-alcoholic extract of Aerva lanata(L.) roots(HAEAL) on ethylene glycol-induced nephrolithiasis in rats.Methods Fifty grams of shade-dried coarsely powdered Aerva lanata(L.) root was successively extracted with organic solvents in increasing order of polarity [petroleum ether(60-80 ℃), chloroform, and ethanol] using a Soxhlet apparatus, and then concentrated. Physical tests including nature, color, odor, and texture were performed on the herbal suspension. In vitro nephrolithiasis assessment was performed by nucleation assay, aggregation assay, and crystal growth assay. Thirty adult male Wistar albino rats were randomly divided into five groups(six rats in each group). Group 1: negative control group without induction or treatment till day 28. Group 2: positive control group receiving a daily oral solution of 0.75% ethylene glycol till day 14, and mixed with distilled water till day 28. Group 3: standard group receiving a daily oral solution of 0.75% ethylene glycol till day 14 and Cystone(750 mg/kg) from day 15 to day 28. Group 4: low dose HAEAL group receiving a daily oral solution of 0.75%ethylene glycol till day 14, and 400 mg/kg HAEAL from day 15 to day 28(1 mL per day). Group 5: high dose HAEAL group receiving a daily oral solution of 0.75% ethylene glycol till day 14,and 800 mg/kg HAEAL from day 15 to day 28(1 mL per day). Urine(urine volume, pH value,appearance, odor, and turbidity) examination and serum test were performed. On day 29, the kidneys were dissected, and histopathology examination was performed to determine the degree of tubular injury.Results The suspension showed stability and aroma with no turbidity at room temperature.The suspension did not show changes in color and odor until day 3, indicating that the preparation was stable for 72 h. Body weight decreased in the positive control group indicating stone formation and changes in water intake. Both standard and HAEAL treatments restored the body weight to normal levels after treatment, indicating the beneficial effects of the treatment. Histopathological examination revealed no significant findings in the negative control group, whereas the positive control group showed inflammation in the kidney parenchyma.Compared with positive control group, there was increase in urine volume and excretion of urinary constituents such as calcium and oxalate(P < 0.01) as well as improved clearance rate(P < 0.05) in HAEAL treatment groups, in addition, the urine pH value of HAEAL groups was increased.Conclusion HAEAL reduced nephrolithiasis formation and had a diuretic effect, which could be used to promote the expulsion of stones. Further studies are needed to enhance the stability of the suspension for the production of better pharmaceutical formulations. 展开更多
关键词 Aerva lanata(L.) NEPHROLITHIASIS Ethylene glycol ANTIOXIDANT Tubular injury DIURESIS Suspension
下载PDF
聚乙二醇修饰脂质体的ABC现象研究进展 被引量:14
8
作者 徐缓 王凯乾 +2 位作者 黄微崴 邓意辉 陈大为 《药学学报》 CAS CSCD 北大核心 2010年第6期677-683,共7页
通常聚乙二醇(polyethylene glycol,PEG)修饰脂质体被认为几乎没有或仅有很低的免疫原性。最新的文献报道,重复注射PEG修饰脂质体发生了免疫反应。当向同一动物体内重复注射(间隔几天)PEG化脂质体时,二次注射的PEG化脂质体导致体内循环... 通常聚乙二醇(polyethylene glycol,PEG)修饰脂质体被认为几乎没有或仅有很低的免疫原性。最新的文献报道,重复注射PEG修饰脂质体发生了免疫反应。当向同一动物体内重复注射(间隔几天)PEG化脂质体时,二次注射的PEG化脂质体导致体内循环时间降低,于肝和脾的聚集量增加,这种现象称为"加速血液清除"(accelerated blood clearance,ABC)现象。该免疫反应使PEG化制剂的发展和临床应用面临严峻的挑战,可能造成药物或基因治疗效率的下降,甚至引起临床的毒副作用。本文综述了ABC现象的定义、验证ABC现象的方法和手段、ABC现象成因的研究进展及影响因素,并对其他PEG修饰载体是否也会发生ABC现象进行了探讨。 展开更多
关键词 乙二醇 脂质体 加速血液清除 -聚乙二醇免疫球蛋白M
原文传递
Preparation and evaluation of a new releasable PEGylated tumor necrosis factor-α(TNF-α) conjugate for therapeutic application 被引量:4
9
作者 DAI ChuanYun FU Ya +7 位作者 CHEN ShaoCheng LI Biao YAO Bo LIU WanHong ZHU LiQing CHEN Nan CHEN Ji ZHANG Qiang 《Science China(Life Sciences)》 SCIE CAS 2013年第1期51-58,共8页
To design a releasable PEGylated TNF-α(rPEG-TNF-α ), a cathepsin B-sensitive dipeptide (Val-Cit moiety) was inserted into conventional PEG-modified TNF- (PEG-TNF- ), facilitating its clinical use for anti-tumor ther... To design a releasable PEGylated TNF-α(rPEG-TNF-α ), a cathepsin B-sensitive dipeptide (Val-Cit moiety) was inserted into conventional PEG-modified TNF- (PEG-TNF- ), facilitating its clinical use for anti-tumor therapy. Comparative pharmaco- kinetic and pharmacodynamic studies showed that the half-lives of both PEGylated forms of TNF-α were ~60-fold greater than that of unmodified TNF-α . In addition, the in vitro bioactivity of rPEG-TNF-α was greater than that of PEG-TNF-α with the same degree of PEG modification. Release of TNF-α from rPEG-TNF-α in vitro was dependent on the presence of cathepsin B and was inhibited by a cathepsin B inhibitor. Despite the potent cytotoxicity of unmodified TNF-α against normal cells, its PEGylated forms at higher TNF-α concentrations showed low cytotoxic activity against these cells. In contrast, both forms of PEGylated TNF-α showed potent cytotoxic activity against the B16 and L929 cell lines, with rPEG-TNF-α being 5- and 9- fold more potent, respectively, than PEG-TNF-α . Moreover, rPEG-TNF-α was a more potent in vivo antitumor agent than PEG-TNF-α . 展开更多
关键词 tumor necrosis factor-α releasable PEGylation DIPEPTIDE anti-tumor effect
原文传递
Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha(TNF-α) against murine fibrosarcoma 被引量:4
10
作者 DAI ChuanYun FU Ya +4 位作者 LI Biao WANG YiGuang ZHANG Xuan WANG JianCheng ZHANG Qiang 《Science China(Life Sciences)》 SCIE CAS 2011年第2期128-138,共11页
To improve the pharmacological profile of tumor necrosis factor alpha(TNF-α),we have synthesized a new PEGylated prodrug,PEG-vcTNF-α,using a cathepsin B-sensitive dipeptide(valine-citrulline,vc) to link branched PEG... To improve the pharmacological profile of tumor necrosis factor alpha(TNF-α),we have synthesized a new PEGylated prodrug,PEG-vcTNF-α,using a cathepsin B-sensitive dipeptide(valine-citrulline,vc) to link branched PEG and TNF-α.PEG-modified TNF-α without the dipeptide linker(PEG-TNF-α) and unconjugated TNF-α were also tested as controls.It was found for the first time that TNF-α released from PEG-vcTNF-α was specifically dependent on the presence of cathepsin B.PEG-vcTNF-α induced higher cytotoxicity and greater apoptosis against L929 murine fibrosarcoma cells than PEG-TNF-α.Reversal of these effects by a cathepsin-B inhibitor confirmed that these effects were mediated by cathepsin B-specific release of TNF-α.In vivo pharmacokinetics studies demonstrated that the plasma stability of PEG-vcTNF-α was significantly increased compared to TNF-α.Finally,the improved anticancer efficacy of PEG-vcTNF-α and the distinct activities among the three formulations confirmed the positive contribution of both PEGylation and the dipeptide linkage to the improved drug-like properties of PEG-vcTNF-α.The results here indicate that linking proteins and PEG via the cathepsin B-sensitive dipeptide may be a promising strategy for developing protein therapeutics. 展开更多
关键词 tumor necrosis factor alpha PEGYLATION cathepsin B-sensitive dipeptide antitumor effect
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部